ID Trials Network
What is the ID Trials Network?
The ID Trials team is made up a group of like-minded clinicians and experienced research coordinators and assistants from across Canada. Our mission is to conduct and support investigator-initiated, pragmatic, randomized controlled trials so that we can replace random care with randomized care and facilitate learning health systems.
We also are interested in creating observational and laboratory analyses which facilitate these ends.
Randomized care
Allows systematic comparison and meaningful inferences between groups
Great way to learn in areas of controversy
Participation in RCT often is of benefit to the patient’s care
Caveats:
Primary outcome, sample size/power and analytic issues can pose challenges
Inferences may be limited by generalizability (eligibility criteria, outcomes)
Random care
Inferences must be made based on observational studies and subject to numerous biases:
Confounding (residual, by severity)
Misclassification bias
Immortal time
For a nice overview of the issues as illustrated by COVID-19 see Tleyjeh et. al, OFID 8(8) 2021
Current Projects
Staphylococcus aureus Network Adaptive Protocol (SNAP) - Canadian lead site.
Nested: Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus aureus Bacteremia (CERT-SNAP) - Lead site
Nested: Daptomycin vs. Vancomycin for the treatment of Methicillin-resistant Staphylococcus aureus bacteremia (DAPTO-SNAP) - Lead site
Nested: Rifampin vs. no rifampin for the treatment of prosthetic valve endocarditis due to S. aureus. - Lead site
Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection (TAPER-V)
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN) - Protocol paper here. Canadian lead site.
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia (LOW-TMP) - Protocol paper here. Lead site.
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides difficile Infection - Participating site
Past Projects
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus aureus Bacteremia - Canadian Lead Site
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) - Participating site.
Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial (STOP COVID 2) - Canadian Lead Site
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 - Canadian Lead Site
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 - Canadian Lead Site
Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia (DASH) - Lead site
Select tools
Other Resources
Summary of outpatient Covid-19 therapeutics
Making sense of sensitivity - a way to visualize pretest and posttest probability for diagnostic tests.
Is it probable - a way to visualize probability from an odds ratio/risk ratio and confidence interval
Our Team - Scientific Directors
Dr. Lee specializes in the design and conduct of pragmatic randomized controlled trials in infectious diseases.
Emily G. McDonald MD MSc FRCPC
Dr. McDonald is the Associate Chair of the Department of Medicine for Quality and Safety, the Scientific Director of the Canadian Medication Appropriateness and Deprescribing Network, and an internationally recognized expert in deprescribing and safer prescribing.
Our Team - Research Coordinators
Lina Petrella
SNAP Trial Canadian Coordinator
Sarah Elsayed
TAPER-V
PETERPEN
LOW-TMP
Camille Valentin
CanTreatCovid - Quebec coordinator
Our Team - Research
Kristen Moran
Research Assistant - Royal Victoria Hospital Site
Iman Husseen
Research Assistant - Montreal General Hospital Site
Suzanne Nolet
Clinical Trials Monitor
Participating Sites Across Canada
We have active clinical trial sites in hospitals in British Columbia, Alberta, Manitoba, Ontario, Quebec, and Newfoundland.